-
Ceribell (CBLL) files $300M mixed shelf
-
Raymond James Starts Ceribell (CBLL) at Strong Buy
-
CeriBell, Inc. (CBLL) Reports Q2 Loss of $0.38
-
Ceribell files patent complaints against Natus Medical with trade commission
-
BTIG Starts Ceribell (CBLL) at Buy
-
TD Cowen: 'Ceribell (CBLL) Should Be a Beneficiary of China/US Tariff Relief'
-
CeriBell, Inc. (CBLL) Reports Q1 Loss of $0.36
-
Ceribell (CBLL): FDA Clears Ceribell’s Clarity Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Age
-
William Blair Reiterates Outperform Rating on Ceribell (CBLL), PT $15
-
Canaccord Genuity Reiterates Buy Rating on Ceribell (CBLL)
-
Ceribell (CBLL) Shares on Watch into Lock-up Expiration
-
CeriBell, Inc. (CBLL) Reports Q4 Loss of $0.40
-
Ceribell (CBLL) PT Raised to $36 at TD Cowen; 'Pipeline Can Add Tech Value'
-
Ceribell (CBLL) Receives Authority to Operate from the U.S. Department of Veterans Affairs
-
Canaccord Genuity Starts Ceribell (CBLL) at Buy
-
TD Cowen Starts Ceribell (CBLL) at Buy
-
JPMorgan Starts Ceribell (CBLL) at Overweight
-
Ceribell (CBLL): New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG
-
Ceribell (CBLL) Opens At $23.26, IPO Priced At $17
-
CeriBell (CBLL) Prices Upsized 10.61M Share IPO at $17/sh
-
CeriBell, Inc (CBLL) Files for Upsized 10.6M Share IPO at a Higher $16-$17/sh Price Range
-
CeriBell, Inc (CBLL) Files for 6.7M Share IPO at $14-$16/sh

